ADAR1 Capital Management LLC Reduces Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

ADAR1 Capital Management LLC lowered its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 65.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,599 shares of the company's stock after selling 245,138 shares during the period. ADAR1 Capital Management LLC owned approximately 0.36% of iTeos Therapeutics worth $1,011,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ITOS. JPMorgan Chase & Co. raised its stake in shares of iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after acquiring an additional 1,601,477 shares during the period. State Street Corp increased its stake in iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after purchasing an additional 211,452 shares during the period. Raymond James Financial Inc. bought a new stake in shares of iTeos Therapeutics during the fourth quarter worth $1,159,000. Trexquant Investment LP grew its holdings in shares of iTeos Therapeutics by 267.2% in the fourth quarter. Trexquant Investment LP now owns 179,966 shares of the company's stock worth $1,382,000 after purchasing an additional 130,960 shares during the last quarter. Finally, Peapod Lane Capital LLC purchased a new position in iTeos Therapeutics in the 4th quarter worth about $836,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Stock Performance

NASDAQ:ITOS traded up $0.47 during trading hours on Friday, reaching $5.65. The company's stock had a trading volume of 367,398 shares, compared to its average volume of 463,499. The company has a market capitalization of $215.80 million, a P/E ratio of -1.79 and a beta of 1.43. The stock has a 50 day moving average price of $6.74 and a two-hundred day moving average price of $7.83. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13. As a group, analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ITOS shares. Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Wedbush reissued an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. decreased their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.